MNKD - Mannkind Corp
IEX Last Trade
6.255
-0.075 -1.199%
Share volume: 4,504,841
Last Updated: Fri 30 Aug 2024 09:59:58 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$6.33
-0.08
-1.19%
Fundamental analysis
27%
Profitability
19%
Dept financing
25%
Liquidity
51%
Performance
30%
Performance
5 Days
16.57%
1 Month
8.68%
3 Months
39.11%
6 Months
59.69%
1 Year
32.07%
2 Year
75.35%
Key data
Stock price
$6.26
DAY RANGE
N/A - N/A
52 WEEK RANGE
$3.17 - $6.44
52 WEEK CHANGE
$0.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: Michael Castagna
Region: US
Website: http://www.mannkindcorp.com/
Employees: 519
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.mannkindcorp.com/
Employees: 519
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
mannkind corporation (nasdaq: mnkd) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. in addition, mannkind is applying our novel technologies and services to support partner development efforts.
Recent news